<div id="readability-page-1"><p>Journey Medical (NASDAQ:DERM - Get Free Report) is expected to release its  Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect Journey Medical to post earnings of ($0.07) per share and revenue of $15.4730 million for the quarter. Interested persons can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:30 PM ET.</p><div><p><span></span><span>Get <strong>Journey Medical</strong> alerts:</span></p></div><p>Journey Medical (NASDAQ:DERM - Get Free Report) last posted its earnings results on Wednesday, March 25th. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.02. The firm had revenue of $16.08 million for the quarter, compared to analyst estimates of $18.86 million. Journey Medical had a negative net margin of 18.48% and a negative return on equity of 46.40%.  On average, analysts expect Journey Medical to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year. </p><h2>Journey Medical Stock Up 1.2%</h2><p>Shares of NASDAQ DERM opened at $5.18 on Wednesday. The company has a market capitalization of $141.57 million, a P/E ratio of -11.02 and a beta of 1.03. Journey Medical has a 52-week low of $4.31 and a 52-week high of $9.56. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.53 and a current ratio of 1.79. The company's 50 day moving average price is $6.28 and its 200-day moving average price is $7.41. </p><h2>Institutional Inflows and Outflows</h2><p>A number of hedge funds and other institutional investors have recently modified their holdings of the company. Jump Financial LLC lifted its position in shares of  Journey Medical by 46.1% during the 4th quarter. Jump Financial LLC now owns 20,183 shares of the company's stock valued at $156,000 after acquiring an additional 6,373 shares during the period.  Bank of America Corp DE lifted its position in shares of  Journey Medical by 421.0% during the 3rd quarter. Bank of America Corp DE now owns 21,537 shares of the company's stock valued at $153,000 after acquiring an additional 17,403 shares during the period.  Marshall Wace LLP acquired a new position in shares of  Journey Medical during the 4th quarter valued at $150,000.  Occudo Quantitative Strategies LP lifted its position in shares of  Journey Medical by 22.3% during the 4th quarter. Occudo Quantitative Strategies LP now owns 18,913 shares of the company's stock valued at $146,000 after acquiring an additional 3,443 shares during the period.  Finally, Wells Fargo &amp; Company MN lifted its position in shares of  Journey Medical by 109.1% during the 4th quarter. Wells Fargo &amp; Company MN now owns 15,748 shares of the company's stock valued at $121,000 after acquiring an additional 8,215 shares during the period. Institutional investors and hedge funds own  7.25% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of brokerages have recently issued reports on DERM. HC Wainwright  restated a &#34;buy&#34; rating and issued a $13.00 price target on shares of Journey Medical in a research report on Thursday, March 26th. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Journey Medical in a research report on Monday, April 20th. Three equities research analysts have rated the stock with a Buy rating, one  has issued  a Hold rating and one  has assigned  a Sell rating to the stock. Based on data from MarketBeat, Journey Medical currently has an average rating of &#34;Hold&#34; and an average price target of $13.00.</p><p><b>Get Our Latest Research Report on DERM</b></p><h2>Journey Medical Company Profile</h2> (Get Free Report)<p>Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.  </p><p>The company's product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Journey Medical</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REVSTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REVSTQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Journey Medical Right Now?</h2><p>Before you consider Journey Medical, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Journey Medical wasn't on the list.</p><p>While Journey Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

DERM

LABU

<p>Journey Medical (NASDAQ: DERM) is set to announce its Q1 2026 earnings on May 13, with analysts predicting a loss of $0.07 per share and revenue of $15.47 million. The company previously reported a loss of $0.04 per share for Q1 2025, exceeding estimates. Journey Medical's stock has seen a 1.2% increase, currently priced at $5.18, with a market cap of $141.57 million. Institutional investors have increased their holdings, and analysts have mixed ratings, with an average target price of $13.00.</p>

Market Beat

Journey Medical

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

iShares Global Healthcare

VanEck Biotech ETF

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

VG Health

Proshares Ultra Nasdaq Biotech

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Bank of America

Wells Fargo

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Journey Medical (DERM) Expected to Announce Earnings on Wednesday